Utility of Far‐Field Potentials as a Biomarker of Neurodegeneration in Spinal Muscular Atrophy
Muscle & Nerve · 2026
DOI: 10.1002/mus.70231 ↗Kurz gefasst
Fachartikel in der Zeitschrift Muscle & Nerve, 2026. Verfasst von Aicee Dawn Calma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Brain and Nerve Research Centre, Concord Clinical School, University of Sydney, Concord Hospital, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Muscular Atrophy, Spinal, Amyotrophic Lateral Sclerosis, Action Potentials, Nerve Degeneration. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction/Aims Far field potentials (FFP) have been proposed as a reliable neurophysiological prognostic biomarker in amyotrophic lateral sclerosis (ALS). This study evaluated the utility of ulnar nerve FFP as a robust research biomarker of lower motor neuron degeneration in spinal muscular atrophy (SMA).
Methods
Peripheral neurophysiological assessments were performed in 13 participants with SMA, 19 with amyotrophic lateral sclerosis (ALS), and 19 healthy controls. The ulnar nerve was stimulated at the wrist, and motor responses were recorded over the abductor digiti minimi (ADM) muscle. Recorded measures included compound muscle action potential (CMAP), FFP and near‐field potential (NFP) amplitudes, and motor unit number index (MUNIX).
Results
The FFP amplitude was significantly lower in SMA participants compared to healthy volunteers ( p < 0.001), but comparable to ALS ( p = 0.11). The FFP amplitude showed strong correlations with the Revised Upper Limb Module (RULM) ( ρ = 0.92), ALS Functional Rating Score‐Revised ( ρ = 0.85), upper limb MRC score ( ρ = 0.89), CMAP amplitude ( ρ = 0.97), NFP amplitude ( ρ = 0.88), and MUNIX values ( ρ = 0.84), all of which were highly statistically significant. Multiple linear regression indicated that FFP amplitude was an independent predictor of RULM ( p < 0.001).
Discussion
FFP amplitude appears to be a promising neurophysiological biomarker for SMA, with potential utility for monitoring disease progression, particularly in a clinical trial setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Brain and Nerve Research Centre, Concord Clinical School, University of Sydney, Concord Hospital, Sydney, New South Wales, Australia.
- Department of Neurology, Unidade Local de Saúde de Almada-Seixal, Almada, Portugal.
- Faculdade de Medicina-Instituto de Medicina Molecular, Centro de Estudos Egas Moniz, Universidade de Lisboa, Lisbon, Portugal.
- Department of Neurology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
- Neurology Division, Ministry of Health Malaysia, Putrajaya, Malaysia.
- Department of Neurosciences, Concord Hospital, Sydney, New South Wales, Australia.
ORCID-Profile: Aicee Dawn Calma, Cláudia Santos Silva, Yukiko Tsuji, Parvathi Menon, Steve Vucic
Zitieren
APA
Calma, A. D., Pavey, N., Silva, C. S., Tsuji, Y., Ghapar, A. A., Morris, K., Kiernan, M. C., Farrar, M. A., Menon, P., & Vucic, S. (2026). Utility of Far‐Field Potentials as a Biomarker of Neurodegeneration in Spinal Muscular Atrophy. Muscle & Nerve. https://doi.org/10.1002/mus.70231
Vancouver
Calma AD, Pavey N, Silva CS, Tsuji Y, Ghapar AA, Morris K, et al. Utility of Far‐Field Potentials as a Biomarker of Neurodegeneration in Spinal Muscular Atrophy. Muscle & Nerve. 2026. doi:10.1002/mus.70231
BibTeX
@article{Calma2026,
author = {Calma, Aicee Dawn and Pavey, Nathan and Silva, Cláudia Santos and Tsuji, Yukiko and Ghapar, Amirul Ab and Morris, Katrina and Kiernan, Matthew C and Farrar, Michelle A and Menon, Parvathi and Vucic, Steve},
title = {Utility of Far‐Field Potentials as a Biomarker of Neurodegeneration in Spinal Muscular Atrophy},
journal = {Muscle & Nerve},
year = {2026},
doi = {10.1002/mus.70231}
}
EUVIMED